Long COVID Treatment Trial-Tirzepatide (LoCITT-T)
The first intervention we are studying is tirzepatide, also known as ZepboundⓇ, a GLP-1 inhibitor that has shown promise in treating many illnesses. We will test whether tirzepatide can alleviate symptoms of Long COVID. We aim to add other interventions as funding becomes available.
Long COVID Wearable Study
We aim to see whether wearable devices improve Long COVID symptom management. Recent studies have shown that activity management can be an effective method of managing and treating symptoms of Long COVID. To continue to gain knowledge of this poorly understood condition, we are conducting The Long COVID Wearable Study. This one-year study will gather survey and wearable data in a bid to better manage symptoms and empower study participants to manage their health.
